Tim Cortese

4 days ago | oncnursingnews.com | Tim Cortese

Givinostat (Duvyzat) has received FDA fast track designation for use in the treatment of polycythemia vera, per a press release from the drug’s developer, Italfarmaco.1Previously, the FDA and the European Medicines Agency (EMA) granted orphan drug designation to givinostat in the same indication. The agent has also received marketing authorizations from the FDA and the UK’s Medicines and Healthcare Products Regulatory Agency for Duchenne muscular dystrophy.

6 days ago | oncnursingnews.com | Tim Cortese

Neurovascular-sparing radiation therapy using the 1.5T Elekta Unity MR-linear accelerator (Linac) reduced radiation exposure to structures critical to erectile function in patients with prostate cancer, according to a press release from Elekta.1 The incidence of erectile dysfunction (ED) at 6 months was 6% with the Elekta Unity MR-Linac and neurovascular sparing and 21% with the same dosage without neurovascular sparing (P = .015); at 12 months, it was 8.5% vs 38%, respectively (P <.001); and...

1 week ago | cancernetwork.com | Tim Cortese

The 1.5T Elekta Unity MR-linear accelerator (Linac) was able to reduce the amount of radiation exposed to key structures responsible for erection in patients with prostate cancer, according to a press release from the developer, Elekta.1 The incidence of erectile dysfunction (ED) at 6 months was 6% with the Elekta Unity MR-Linac and neurovascular sparing and 21% with the same dosage without neurovascular sparing (P = .015); at 12 months, it was 8.5% vs 38%, respectively (P <.001); and at 18...

1 week ago | cancernetwork.com | Tim Cortese

The FDA has granted fast track designation to givinostat (Duvyzat) for the treatment of patients with polycythemia vera, according to a press release from the developer, Italfarmaco.1Previously, the FDA and the European Medicines Agency (EMA) granted orphan drug designation to givinostat in the same indication. The agent has also received marketing authorizations from the FDA and the UK’s Medicines and Healthcare Products Regulatory Agency for Duchenne muscular dystrophy.

1 week ago | cancernetwork.com | Tim Cortese

Hyperthermic intrathoracic chemotherapy (HITOCH) added to macroscopic complete resection (MCR) showed potential improvements to survival outcomes while appearing safe and feasible in patients with malignant pleural mesothelioma (MPM), according to findings from a systematic review (CRD42024588823) published in the World Journal of Surgical Oncology.1 Data from 6 studies showed a survival benefit that ranged from 13 to 35 months in patients who received HITOCH vs 11 to 22.8 months in patients...